Cargando…
Harnessing Human Cross-Presenting CLEC9A(+)XCR1(+) Dendritic Cells for Immunotherapy
Autores principales: | Tullett, Kirsteen M., Lahoud, Mireille H., Radford, Kristen J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033245/ https://www.ncbi.nlm.nih.gov/pubmed/24904587 http://dx.doi.org/10.3389/fimmu.2014.00239 |
Ejemplares similares
-
RNF41 regulates the damage recognition receptor Clec9A and antigen cross-presentation in mouse dendritic cells
por: Tullett, Kirsteen M, et al.
Publicado: (2020) -
Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A
por: Lahoud, M. H., et al.
Publicado: (2021) -
Cross-Presenting XCR1(+) Dendritic Cells as Targets for Cancer Immunotherapy
por: Audsley, Katherine M., et al.
Publicado: (2020) -
The Role of XCR1 and its Ligand XCL1 in Antigen Cross-Presentation by Murine and Human Dendritic Cells
por: Kroczek, Richard A., et al.
Publicado: (2012) -
Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells
por: Masterman, Kelly-Anne, et al.
Publicado: (2020)